Josh Martin

speaker
87 appearances 3 recordings 1 series first heard Jul 2026 last heard 31 Aug

Josh Martin’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months
2 · Aug OctJan 26AprJulnow

Recordings per month over the last 12 months — 3 in all, peaking in Aug 2026 with 2.

Appearances

newest first · ▶ plays the moment
And one thing I just wanted to point out was the difference between the two airlines and how much revenue they generate from these add-on fees.
It's quite clear now that we've done this little experiment, but forty four percent of Wizier's revenue comes from these add on fees.
For Turkish it's less than ten percent.
This is the opioid settlement money.
The payouts from the companies that were sued over the crisis.
Purdue Pharma, Johnson & Johnson, the big distributors, the pharmacy chains.
And it's estimated to be around $55 to $57 billion paid out over the next 10 to 16 years, split across all 50 states.
That's about a billion dollars per state.
And some of that money is now buying the antidote.
Yeah, so nationally, at least three settlements ended up letting states take part of their payouts in naloxone rather than cash.
Teva, one of the world's biggest generic drug makers, Amnil, and Hikma.
Teva was the first to pay an antidote.
It agreed to hand over up to $1.2 billion in generic naloxone, which according to Teva is about 9.6 million kits.
Amniel's deal was $88.5 million in cash, plus up to $177 million in naloxone.
Hikma's is much smaller, it's just under $35 million of product, 277,000 kits.
And all of the settlement documents state that the companies do not admit liability or wrongdoing, and all three agreements value a kit at exactly the same price, $125, more than double the current over-the-counter price.
Yeah, Hikma defends using that list price.
It calls the figure a widely recognised pharmaceutical industry benchmark.
Consistent, transparent and objective.
Its focus, it says, was on making an important public health impact and not on comparing a product contribution with a hypothetical equivalent cash payment.
Showing 61–80 of 87 · page 4 of 5 ← Previous Next →